Clinical trials: Hospitalized COVID-19
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.
- Trial name
- NCT05706454
- Testing
- Ramatroban
- Where
- 7 sites in India
- Volunteers
- 324 people
- Sponsor
- KARE Biosciences
COVID
Maraviroc in Patients With Moderate and Severe COVID-19
Maraviroc, a C-C Chemokine Receptor 5 (CCR5) antagonist, is well-tolerated without significant side effects in its current use in patients with HIV.
- Trial name
- NCT04435522
- Testing
- Maraviroc
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Rhode Island Hospital
COVID-19
Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19
This is a multi-center, randomized, triple-blind, placebo-controlled (RCT) study to evaluate the efficacy and safety of Dapsone in older adults, and/or in adult patients (≥40yrs of age) with at least one high-risk comorbidity…
- Trial name
- DAP-CORONA (NCT04935476)
- Testing
- Dapsone 85 mg PO BID
- Where
- 7 sites in United States, Canada
- Volunteers
- 3,000 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Covid19
Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)
This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- NCT06729593
- Testing
- Remdesivir, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 87 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, Hospitalized COVID-19 Patients
LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients
This study aims first to assess the efficacy, safety, and effectiveness of the LUSZ COVID-19 therapy consisting of a comparative study of three different treatment approaches: antiviral, antiretroviral, and immunosuppressive IL-6…
- Trial name
- LUSZ_AVIST (NCT05925140)
- Testing
- Lopinavir / Ritonavir, Remdesivir (RDV), Tocilizumab
- Where
- 2 sites in Lebanon
- Volunteers
- 1,000 people
- Sponsor
- Lebanese University
COVID-19, Oscillation and Lung Expansion
Oscillation and Lung Expansion Therapy in Patients With COVID-19
A Pilot Study of the Use of Oscillation and Lung Expansion (OLE) Therapy in Patients Hospitalized with COVID-19
- Trial name
- NCT04582214
- Testing
- MetaNeb® System
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Hill-Rom
COVID-19 Pneumonia, Viral Pneumonia
Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias
This is an open-label phase 1 clinical trial of allogeneic umbilical cord derived mesenchymal stromal cells (MSCs) for hospitalized individuals with COVID-19 or other viral pneumonias.
- Trial name
- SAMPSON-1 (NCT05286255)
- Testing
- Allogeneic Mesenchymal Stromal Cells
- Where
- United States
- Sponsor
- Medical University of South Carolina
COVID-19
The KIN-FAST Trial (KIN001 For Accelerated Symptoms Termination) in Non Hospitalized Patients Infected With SARS-CoV-2
Clinical trial on safety and efficacy of KIN001 in non-hospitalized patients with COVID-19.
- Trial name
- KIN-FAST (NCT05659459)
- Testing
- KIN001
- Where
- 8 sites in Germany, Switzerland
- Volunteers
- 17 people
- Sponsor
- Kinarus AG
COVID-19 Pneumonia
A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
- Trial name
- REMDACTA (NCT04409262)
- Testing
- Remdesivir, Tocilizumab
- Where
- 54 sites in United States, Brazil and 2 more
- Volunteers
- 649 people
- Sponsor
- Hoffmann-La Roche
Covid-19, SARS-CoV2
Efficacy and Safety of BIO101 in the Prevention of Respiratory Deterioration in Hospitalized COVID-19 Patients
The COVA clinical study is a global multicentric, double-blind, placebo-controlled, group sequential and adaptive 2 parts phase 2-3 study targeting in participants with SARS-CoV-2 pneumonia.
- Trial name
- COVA (NCT04472728)
- Testing
- BIO101
- Where
- 22 sites in United States, Belgium and 3 more
- Volunteers
- 238 people
- Sponsor
- Biophytis
COVID-19
Arginine Replacement Therapy in COVID-19
This study aims to investigate if receiving doses of arginine (a protein in the body) will improve mitochondria function in children with COVID-19. The study will be performed at the Children's Healthcare of Atlanta, Arthur M.
- Trial name
- ART-COVID19 (NCT05855330)
- Testing
- Arginine Hydrochloride
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Emory University
Covid19, Lung Function Decreased
Patient-reported Outcomes and Lung Function After Hospitalization for COVID-19
A multicenter prospective cohort study performed at 6 major teaching hospitals in Southern Norway to study patient reported outcomes, lung function and pulmonary CT in patients at 3 and 12 months after hospitalization for…
- Trial name
- PROLUN (NCT04535154)
- Testing
- No interventions
- Where
- Norway
- Volunteers
- 264 people
- Sponsor
- University Hospital, Akershus
COVID-19 Pneumonia
Efficacy of the Early Prone-positioning in Hospitalized Patients With Mild Covid-19 Pneumonia
The study aims to evaluate if the early prone-positioning in awake patients with mild Covid-19 pneumonia can reduce the need of high-flow oxygen-therapy, invasive or non-invasive ventilation and prevent the worsening of clinical…
- Trial name
- EpCOT (NCT05008380)
- Testing
- prone positioning
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- University of Milano Bicocca
COVID-19, Pneumothorax
The Relationship Between Covid-19 and Pneumothorax in Patients Hospitalized With Covid-19 During the Pandemic
It is aimed to examine the retrospective features of covid-19 patients followed in our hospital with pneumothorax.
- Trial name
- NCT05677776
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Erol Olcok Corum Training and Research Hospital
Duration of Hospitalization, Clinical Manifestation of COVID-19
OBSERVATIONAL STUDY OF COMPARISON EFFECTIVITY BETWEEN REMDESIVIR AND FAVIPIRAVIR IN SURABAYA, INDONESIA
In order to compare the effectiveness between Remdesivir and Favipiravir, an observational analytic study using a retrospective cohort design. Eighty-eight medical records of COVID-19 patients from January to August 2021
- Trial name
- NCT05222113
- Testing
- Remdesivir
- Where
- Indonesia
- Volunteers
- 87 people
- Sponsor
- Bernadette Dian Novita, MD.,PhD
COVID-19
LACTYFERRIN™ Forte and ZINC Defense™ and Standard of Care (SOC) vs SOC in the Treatment of Non-hospitalized Patients With COVID-19
The goal of this clinical trial is to learn about the safety and efficacy of Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™ in non-hospitalized patients with COVID-19.
- Trial name
- NCT05783180
- Testing
- Sesderma LACTYFERRIN™ Forte and Sesderma ZINC Defense™
- Where
- United States
- Sponsor
- Jose David Suarez, MD
Covid19, Hypoxemia
Evaluation of a Low-cost CPAP Device on Hospitalized COVID-19 Patients
The aim of this study is to evaluate the preliminary safety and performance of a low-cost locally-made Venturi-based Non-invasive Positive Pressure Ventilator (NIPPV) device for hypoxemic COVID-19 patients.
- Trial name
- OxyJet-CPAP (NCT04681859)
- Testing
- High Flow Nasal Oxygen (HFNO) treatment, Continuous Positive Airway Pressure (CPAP) therapy using OxyJet
- Where
- Bangladesh
- Volunteers
- 45 people
- Sponsor
- Bangladesh University of Engineering and Technology
COVID-19
BRII-196/BRII-198 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)
This study looks at the safety and effectiveness of BRII-196/BRII-198 in treating COVID-19 in people who have been hospitalized with the infection.
- Trial name
- NCT05780424
- Testing
- BRII-196, BRII-198, Remdesivir
- Where
- 107 sites in United States, Denmark and 6 more
- Volunteers
- 353 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19
This is a platform trial to conduct a series of randomized, double-blind, placebo-controlled trials using common assessments and endpoints in hospitalized adults diagnosed with Coronavirus Disease 2019 (COVID-19).
- Trial name
- NCT04583969
- Testing
- Lenzilumab, Remdesivir
- Where
- 55 sites in United States, South Korea
- Volunteers
- 527 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Virus Diseases, Infection Viral
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.
- Conditions
- Virus Diseases, Infection Viral, Corona Virus Infection
- Trial name
- ProPAC-COVID (NCT04322396)
- Testing
- Azithromycin, Hydroxychloroquine
- Where
- 8 sites in Denmark
- Volunteers
- 117 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark